APM Aptorum Group Ltd
Price Chart
Executive Summary
Aptorum Group filed Pre-Effective Amendment No. 4 to its S-4 registration statement, providing the definitive proxy statement/prospectus for the special meeting on June 9, 2026, to approve the merger with DiamiR Biosciences. The merger will result in existing Aptorum shareholders owning approximately 30% of the combined company, while DiamiR stockholders will own approximately 70%. The filing confirms that CEO Ian Huen, who controls 86.71% of voting power, has already committed to vote in favor of all proposals, making shareholder approval a foregone conclusion. The merger is a condition to Aptorum's continued viability, as the company has a going concern warning, no revenue, and limited cash.
Actionable Insight
The merger is virtually certain to be approved given Huen's voting control. Existing APM shareholders face massive dilution to 30% ownership in a combined entity with no revenue and a going concern. The stock may trade down toward the implied value of the combined entity. Monitor for any termination of the merger agreement before June 30, 2026, which would likely trigger a termination fee and further downside.
Key Facts
- Existing Aptorum shareholders will own approximately 30% of the combined company post-merger, while DiamiR stockholders will own approximately 70%.
- CEO Ian Huen controls 86.71% of voting power and has agreed to vote for all proposals, ensuring approval.
- Aptorum has a going concern warning from its auditor, no revenue, and limited cash ($3.5M as of Dec 31, 2025).
- The merger is expected to close before 2027, with a special meeting scheduled for June 9, 2026.
- Aptorum must maintain at least $2.26M in cash and $1.644M in working capital at closing.
- DiamiR has never generated revenue from product sales and has an accumulated deficit of $6.17M as of Feb 28, 2026.
- The combined company will be renamed Niki BioSolutions, Inc. and trade under the symbol NIKI.
- A reverse stock split (2:1 to 10:1) is proposed to maintain Nasdaq listing compliance.
Financial Impact
Existing APM shareholders diluted to 30% ownership; DiamiR valued at implied $18.7M based on conversion ratio; Aptorum had $3.5M cash as of Dec 31, 2025
Risk Factors
- Massive dilution: existing shareholders reduced to 30% ownership
- Going concern risk: both Aptorum and DiamiR have going concern warnings
- Merger may not close if cash conditions ($2.26M minimum) are not met
- Combined company has no approved products and no revenue
- Nasdaq delisting risk if reverse split fails to maintain bid price
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-056820 |
| Document: ea0290494-01.htm | 0001213900-26-056820 |
| Document: ea029049401ex23-2.htm | 0001213900-26-056820 |
| Document: ea029049401ex23-1.htm | 0001213900-26-056820 |
| Document: 0001213900-26-056820-index-headers.html | 0001213900-26-056820 |
| Document: 0001213900-26-056820-index.html | 0001213900-26-056820 |
| Document: 0001213900-26-056820.txt | 0001213900-26-056820 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
EFFECT
| $1.09 $1.01 | ▼ −7.34% | ▼ −4.74% | $1.12 (+2.75%) |
|
May 14, 2026
26d ago
|
6-K
| $0.8230 $0.8570 | ▼ −4.13% | ▼ −4.19% | $1.12 (−36.09%) |
|
Mar 27, 2026
10w ago
|
20-F
| $0.8380 $0.7960 | ▲ +5.01% | ▲ +7.90% | $1.12 (−33.65%) |
|
Mar 6, 2026
13w ago
|
Press Release
| $0.8000 $0.7930 | ▲ +0.88% | ▲ +0.69% | $1.12 (−40.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access